Nectar Lifescience Ltd (NECLIFE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 216478, "name": "Nectar Lifesci.", "stock_name": "Nectar Lifesci.", "full_name": "Nectar Lifescience Ltd", "name_url": "stocks-analysis/nectar-lifesci", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "10.51", "chg": -0.2, "chgp": "-1.87%", "dir": -1, "prev_price": "10.71", "mcapval": "209.00 Cr", "mcap": "Micro Cap", "scripcode": 532649, "symbol": "NECLIFE", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE023H01027", "curr_date": "Aug 04, 03:30 PM", "curr_time": "04:18 AM", "last_traded_at": "Aug 04, 03:30 PM IST", "bse_nse_vol": "2.23 lacs", "exc_status": "Active", "traded_date": "Aug 04, 2026", "traded_date_str": "2026 08 04", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nectar-lifesci-216478-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Nectar Lifescience Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-4121157", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NectarLifescien_mojoScore_4121157.png", "date": "2026-07-26 10:10:16", "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "Nectar Lifescience Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-4103716", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NectarLifescien_mojoScore_4103716.png", "date": "2026-07-15 10:10:33", "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 July 2026, providing investors with an up-to-date view of the company’s performance and outlook." }, { "title": "Nectar Lifescience Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-4088387", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NectarLifescien_mojoScore_4088387.png", "date": "2026-07-04 10:10:19", "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing." }, { "title": "Nectar Lifescience Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-4068965", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NectarLifescien_mojoScore_4068965.png", "date": "2026-06-23 10:10:32", "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 23 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Nectar Lifescience Declines 3.78% Amid Mounting Losses and Margin Pressures", "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-declines-378-amid-mounting-losses-and-margin-pressures-4053114", "imagepath": "", "date": "2026-06-14 15:00:47", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>1 June:</strong> Q4 FY26 results reveal deepening operational losses</p>\n <p><strong>2 June:</strong> Flat quarterly performance reported amidst margin pressures</p>\n <p><strong>5 June:</strong> Week closes at Rs.11.96, down 3.78%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.12.21</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.11.96</div><div class=\"stat-change negative\">-3.78%</div></div>\n <div class=\"stat-item\"><div cla..." }, { "title": "Nectar Lifescience Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-4046505", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NectarLifescien_mojoScore_4046505.png", "date": "2026-06-11 10:10:22", "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "Nectar Lifescience Ltd Reports Flat Quarterly Performance Amidst Margin Pressures", "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-ltd-reports-flat-quarterly-performance-amidst-margin-pressures-4030802", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NectarLifescien_fintrenddot_4030802.png", "date": "2026-06-02 11:00:11", "description": "Nectar Lifescience Ltd reported a flat financial performance for the quarter ended March 2026, marking a notable improvement from previous negative trends but still reflecting significant operational challenges. Despite a stabilisation in revenue growth, the company’s profitability metrics deteriorated sharply, underscoring persistent margin pressures in a competitive pharmaceutical sector." }, { "title": "Are Nectar Lifescience Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-nectar-lifescience-ltd-latest-results-good-or-bad-4028007", "imagepath": "", "date": "2026-06-01 19:23:49", "description": "Nectar Lifescience Ltd's latest financial results for Q4 FY26 reveal significant operational challenges and a concerning financial trajectory. The company reported a consolidated net loss of ₹67.92 crores, which marks a substantial deterioration compared to previous periods. Standalone results also reflect a net loss of ₹37.21 crores, a stark contrast to a profit of ₹0.30 crores in the prior quarter, indicating a severe decline in profitability.\n\nRevenue generation remains critically low, with standalone revenue reported at just ₹1.29 crores, showing minimal recovery from the previous quarter's ₹0.00 crores. This erratic revenue pattern raises questions about the company's operational stability and market demand for its products. The operating profit before depreciation, interest, and tax (PBDIT) fell to a record loss of ₹57.24 crores, illustrating a complete operational breakdown.\n\nThe company’s financial ..." }, { "title": "Nectar Lifescience Q4 FY26: Mounting Losses Signal Deepening Operational Crisis", "link": "https://www.marketsmojo.com/news/result-analysis/nectar-lifescience-q4-fy26-mounting-losses-signal-deepening-operational-crisis-4026922", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NectarLifescien_quaterlyResult_4026922.png", "date": "2026-06-01 13:03:14", "description": "Nectar Lifescience Ltd., a micro-cap pharmaceutical company specialising in cephalosporins, reported a devastating quarter-on-quarter deterioration in Q4 FY26, with consolidated net losses ballooning to ₹67.92 crores—a staggering 575.96% increase from the previous quarter's ₹14.27 crore profit. The company's standalone net loss stood at ₹37.21 crores, marking a catastrophic reversal from operational stability and raising serious questions about the viability of its business model." } ], "total": 628, "sid": "216478", "stock_news_url": "https://www.marketsmojo.com/news/nectar-lifescience-216478" }, "announcements": [ { "caption": "Update On Slump Sale", "datetime": "23-Jul-2026", "details": "Please find attached herewith letter w.r.t.: Update on Slump Sale", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Change in Registered Office Address", "datetime": "11-Jul-2026", "details": "We wish to inform you that the board of directors of Nectar Lifesciences Limited (Company) has change the registered office of the Company", "source": "BSE" }, { "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018", "datetime": "04-Jul-2026", "details": "Please find attached herewith the certificate as per caption regulations", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Nectar Lifescience Ltd has declared <strong>5%</strong> dividend, ex-date: 11 Sep 20", "dt": "2020-09-11", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Nectar Lifescience Ltd has announced <strong>1:10</strong> stock split, ex-date: 12 Nov 08", "dt": "2008-11-12", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

1 June: Q4 FY26 results reveal deepening operational losses

2 June: Flat quarterly performance reported amidst margin pressures

5 June: Week closes at Rs.11.96, down 3.78%

Read full news article

Nectar Lifescience Ltd is Rated Strong Sell

2026-06-11 10:10:22

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Nectar Lifescience Ltd Reports Flat Quarterly Performance Amidst Margin Pressures

2026-06-02 11:00:11

Nectar Lifescience Ltd reported a flat financial performance for the quarter ended March 2026, marking a notable improvement from previous negative trends but still reflecting significant operational challenges. Despite a stabilisation in revenue growth, the company’s profitability metrics deteriorated sharply, underscoring persistent margin pressures in a competitive pharmaceutical sector.

Read full news article

Are Nectar Lifescience Ltd latest results good or bad?

2026-06-01 19:23:49

Nectar Lifescience Ltd's latest financial results for Q4 FY26 reveal significant operational challenges and a concerning financial trajectory. The company reported a consolidated net loss of ₹67.92 crores, which marks a substantial deterioration compared to previous periods. Standalone results also reflect a net loss of ₹37.21 crores, a stark contrast to a profit of ₹0.30 crores in the prior quarter, indicating a severe decline in profitability. Revenue generation remains critically low, with standalone revenue reported at just ₹1.29 crores, showing minimal recovery from the previous quarter's ₹0.00 crores. This erratic revenue pattern raises questions about the company's operational stability and market demand for its products. The operating profit before depreciation, interest, and tax (PBDIT) fell to a record loss of ₹57.24 crores, illustrating a complete operational breakdown. The company’s financial ...

Read full news article

Nectar Lifescience Q4 FY26: Mounting Losses Signal Deepening Operational Crisis

2026-06-01 13:03:14

Nectar Lifescience Ltd., a micro-cap pharmaceutical company specialising in cephalosporins, reported a devastating quarter-on-quarter deterioration in Q4 FY26, with consolidated net losses ballooning to ₹67.92 crores—a staggering 575.96% increase from the previous quarter's ₹14.27 crore profit. The company's standalone net loss stood at ₹37.21 crores, marking a catastrophic reversal from operational stability and raising serious questions about the viability of its business model.

Read full news article